News
CERT
8.52
+1.19%
0.10
Weekly Report: what happened at CERT last week (0914-0918)?
Weekly Report · 1d ago
Certara: Hold Rating Reiterated as Transition Risks Offset Long-Term Biosimulation and AI Upside; $9 Price Target Maintained
TipRanks · 5d ago
Certara Stock Is Up 5.0% What's Changed After Software Growth And Job Cuts
Simply Wall St · 5d ago
Weekly Report: what happened at CERT last week (0907-0911)?
Weekly Report · 09/14 10:09
Certara (CERT) Software Growth Meets Restructuring Costs, Is The Stock Still A Bargain?
Simply Wall St · 09/14 08:12
Weekly Report: what happened at CERT last week (0831-0904)?
Weekly Report · 09/07 10:03
Weekly Report: what happened at CERT last week (0824-0828)?
Weekly Report · 08/31 10:10
HHS said to be eyeing two new FDA deputy commissioners for technology and drugs
Seeking Alpha · 08/25 17:53
Weekly Report: what happened at CERT last week (0817-0821)?
Weekly Report · 08/24 10:10
Weekly Report: what happened at CERT last week (0810-0814)?
Weekly Report · 08/17 10:11
How Investors Are Reacting To Certara (CERT) Expanding Buybacks Amid Wider Losses And Leadership Changes
Simply Wall St · 08/11 18:28
Weekly Report: what happened at CERT last week (0803-0807)?
Weekly Report · 08/10 10:07
Certara Corrects EBITDA Disclosure in Earnings Presentation
TipRanks · 08/07 20:50
Certara (CERT) Could Be 9% Undervalued On Earnings Guidance And Buyback News
Simply Wall St · 08/07 16:36
Certara price target raised to $7 from $6 at Baird
TipRanks · 08/05 14:27
Certara price target lowered to $9 from $10 at Morgan Stanley
TipRanks · 08/05 14:14
Certara: Hold Rating Maintained as Turnaround Progress Offsets Near-Term Pressures; Price Target Trimmed from $10 to $9
TipRanks · 08/05 13:44
BMO Capital Sticks to Its Hold Rating for Certara (CERT)
TipRanks · 08/05 11:39
Barclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5
Benzinga · 08/05 11:05
Certara price target raised to $7.50 from $6.50 at Barclays
TipRanks · 08/05 09:10
More
Webull provides a variety of real-time CERT stock news. You can receive the latest news about Certara, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CERT
Certara, Inc. is a provider of biosimulation science, technology, and consulting services for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical and biotech industry. The Company's proprietary biosimulation platforms are built on biology, chemistry, and pharmacology principles with proprietary mathematical algorithms that model how medicines and diseases behave in the body. It has developed scientifically-based solutions for the collection, standardization, validation, storage, and analysis of the preclinical, clinical and evidence data needed for MIDD. These data solutions are used internally and industry-wide by life sciences companies. The Company applies AI capabilities within established modeling environments and under the supervision of experienced scientists and regulatory experts. Its modeling platforms and curated datasets position it to incorporate emerging AI techniques in a controlled and scientifically rigorous manner.